<DOC>
	<DOCNO>NCT00827099</DOCNO>
	<brief_summary>RATIONALE : Giving low dos chemotherapy donor umbilical cord blood transplant help stop growth cancer cell . It may also stop patient 's immune system reject donor 's stem cell . The donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Sometimes transplanted cell donor also make immune response body 's normal cell . Giving tacrolimus mycophenolate mofetil transplant may stop happen . PURPOSE : This phase II trial study well give umbilical cord blood transplant together fludarabine , melphalan , antithymocyte globulin work treat patient hematologic cancer .</brief_summary>
	<brief_title>Umbilical Cord Blood ( UCB ) Transplant , Fludarabine , Melphalan , Anti-thymocyte Globulin ( ATG ) Treating Patients With Hematologic Cancer</brief_title>
	<detailed_description>OBJECTIVES : Primary - To evaluate 100-day transplant-related ( non-relapse ) mortality patient hematologic malignancy undergo reduced-intensity conditioning comprise fludarabine phosphate , melphalan , anti-thymocyte globulin follow sequential umbilical cord blood transplantation ( UCBT ) 2 partially-matched unrelated donor . Secondary - To evaluate 12-month transplant-related ( non-relapse ) mortality . - To evaluate day neutrophil engraftment ( ANC &gt; 500/mm³ ) . - To evaluate day platelet engraftment ( platelet count &gt; 20,000/mm³ [ unsupported ] ) . - To evaluate risk acute chronic graft-vs-host disease . - To evaluate percent donor chimerism contribution cord unit . - To evaluate relapse rate . - To evaluate disease-free overall survival . - To evaluate transfusion support need UCBT recipient . OUTLINE : - Conditioning regimen : Patients receive fludarabine phosphate IV 30 minute day -7 -3 , melphalan IV 30-60 minute day -2 , anti-thymocyte globulin IV 4-6 hour day -4 -2 . - Transplantation : Patients undergo two sequential umbilical cord blood transplantation day 0 . - Graft-vs-host disease ( GVHD ) prophylaxis : Patients receive tacrolimus IV continuously orally twice daily begin day -1 continue day 60 , follow taper day 180 absence GVHD . Patients also receive mycophenolate mofetil IV orally twice daily begin day 0 continue day 30 , follow taper day 60 absence GVHD . After completion study treatment , patient follow periodically .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Multiple Myeloma</mesh_term>
	<mesh_term>Neoplasms , Plasma Cell</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Plasmacytoma</mesh_term>
	<mesh_term>Myeloproliferative Disorders</mesh_term>
	<mesh_term>Tacrolimus</mesh_term>
	<mesh_term>Fludarabine phosphate</mesh_term>
	<mesh_term>Antilymphocyte Serum</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Fludarabine</mesh_term>
	<mesh_term>Vidarabine</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis hematologic malignancy reducedintensity allogeneic stem cell transplantation deem clinically appropriate , include follow : Chronic myelogenous leukemia , meet one follow criterion : In first chronic phase AND fail imatinib mesylate therapy , defined failure obtain hematologic remission 3 month major cytogenetic response ( Ph+ cell &lt; 35 % ) 12 month , demonstrate clonal evolution disease progression therapy In accelerated phase &lt; 15 % blast In blast crisis enter second chronic phase follow induction chemotherapy Acute myelogenous leukemia , meet one follow criterion : In second subsequent completion remission* Failed primary induction chemotherapy , subsequently enter complete remission* ≤ 2 subsequent reinduction chemotherapy treatment ( ) In first complete remission* poorrisk cytogenetics NOTE : *Complete remission define &lt; 5 % blast bone marrow , definitive evidence disease morphology , flow cytometry , genetic study , circulate blast . Neutrophil platelet count recovery require . Acute lymphoblastic leukemia , meet one follow criterion : In second subsequent complete remission In first complete remission AND ( 9 ; 22 ) Myelodysplastic syndrome , meet follow criterion : Highrisk disease , define International Prognostic Scoring System score ≥ 1.5 Less 10 % blast time study enrollment Chronic myelomonocytic leukemia Less 10 % blast time study enrollment Myeloid metaplasia myelofibrosis poorrisk feature , meet one follow criterion : Age &lt; 55 year AND Lille score 1 Lille score 2 Hemoglobin &lt; 10 g/dL AND abnormal karyotype Chronic lymphocytic leukemia/prolymphocytic leukemia , meet follow criterion : Rai stage IIV disease Failed ≥ 1 prior chemotherapy regimen , include fludarabine , autologous stem cell transplantation Chemosensitive stable , nonbulky disease prior transplant Received ≤ 3 prior chemotherapy regimen ( monoclonal antibody therapy involvedfield radiotherapy consider prior regimen ) Lowgrade Bcell nonHodgkin lymphoma ( NHL ) ( small lymphocytic lymphoma , follicular center [ grade 1 2 ] lymphoma , marginal zone lymphoma ) , meet follow criterion : Failed ≥ 1 prior chemotherapy regimen autologous stem cell transplantation Chemosensitive stable , nonbulky disease prior transplant Received ≤ 3 prior chemotherapy regimen ( monoclonal antibody therapy involvedfield radiotherapy consider prior regimen ) Intermediategrade Bcell Tcell NHL mantle cell NHL , meet follow criterion : Failed achieve remission recur either conventional chemotherapy autologous stem cell transplantation Chemosensitive , nonbulky disease prior transplant Hodgkin lymphoma , meet follow criterion : Relapsed prior autologous stem cell transplantation ≥ 2 combination chemotherapy regimen AND ineligible autologous peripheral blood stem cell transplantation Chemosensitive , nonbulky disease prior transplant Multiple myeloma , meet one follow criterion : Relapsed autologous stem cell transplantation Relapsed conventional therapy AND candidate autologous stem cell transplantation No HLAmatched relate unrelated donor available Has two umbilical cord blood unit available match ≥ 4/6 HLA A , B , DRB1 patient ( HLA C DQ use match strategy ) Total combine nucleate cell dose 2 umbilical cord blood unit must &gt; 3.7 x 10^7 nucleated cells/kg ( prefreeze dose ) NOTE : A new classification scheme adult nonHodgkin 's lymphoma adopt PDQ . The terminology `` indolent '' `` aggressive '' lymphoma replace former terminology `` low '' , `` intermediate '' , `` high '' grade lymphoma . However , protocol us former terminology . PATIENT CHARACTERISTICS : Karnofsky performance status 80100 % Adapted , weight Charlson Comorbidity Index &lt; 3 Serum creatinine ≤ 2.0 mg/dL AST ALT &lt; 3 time upper limit normal ( ULN ) Bilirubin &lt; 1.5 time ULN Not pregnant nursing LVEF ≥ 40 % DLCO &gt; 50 % No hypoxia rest oxygen saturation &lt; 92 % room air ( correct bronchodilator therapy ) No active opportunistic infection ( e.g. , fungal pneumonia , tuberculosis , viral infection ) No active hepatitis B C infection , opinion gastroenterologist transplant committee , place patient moderate highrisk develop severe hepatic disease No HIV infection PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2012</verification_date>
	<keyword>accelerated phase cml</keyword>
	<keyword>adult ALL remission</keyword>
	<keyword>adult AML remission</keyword>
	<keyword>adult AML 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult AML inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 15 ; 17 ) ( q22 ; q12 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>blastic phase chronic myelogenous leukemia</keyword>
	<keyword>chronic myelomonocytic leukemia</keyword>
	<keyword>chronic phase chronic myelogenous leukemia</keyword>
	<keyword>prolymphocytic leukemia</keyword>
	<keyword>recurrent adult T-cell leukemia/lymphoma</keyword>
	<keyword>relapse chronic myelogenous leukemia</keyword>
	<keyword>secondary acute myeloid leukemia</keyword>
	<keyword>refractory chronic lymphocytic leukemia</keyword>
	<keyword>stage I chronic lymphocytic leukemia</keyword>
	<keyword>stage II chronic lymphocytic leukemia</keyword>
	<keyword>stage III chronic lymphocytic leukemia</keyword>
	<keyword>stage IV chronic lymphocytic leukemia</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
	<keyword>anaplastic large cell lymphoma</keyword>
	<keyword>angioimmunoblastic T-cell lymphoma</keyword>
	<keyword>cutaneous B-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent cutaneous T-cell non-Hodgkin lymphoma</keyword>
	<keyword>recurrent mycosis fungoides/Sezary syndrome</keyword>
	<keyword>adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
	<keyword>Waldenstrom macroglobulinemia</keyword>
	<keyword>extranodal marginal zone B-cell lymphoma mucosa-associated lymphoid tissue</keyword>
	<keyword>nodal marginal zone B-cell lymphoma</keyword>
	<keyword>splenic marginal zone lymphoma</keyword>
	<keyword>recurrent adult diffuse large cell lymphoma</keyword>
	<keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
	<keyword>recurrent adult diffuse small cleave cell lymphoma</keyword>
	<keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
	<keyword>recurrent grade 1 follicular lymphoma</keyword>
	<keyword>recurrent grade 2 follicular lymphoma</keyword>
	<keyword>recurrent grade 3 follicular lymphoma</keyword>
	<keyword>recurrent mantle cell lymphoma</keyword>
	<keyword>recurrent marginal zone lymphoma</keyword>
	<keyword>recurrent small lymphocytic lymphoma</keyword>
	<keyword>chronic idiopathic myelofibrosis</keyword>
	<keyword>stage I multiple myeloma</keyword>
	<keyword>stage II multiple myeloma</keyword>
	<keyword>stage III multiple myeloma</keyword>
	<keyword>refractory multiple myeloma</keyword>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
</DOC>